Thursday 23 November 2017, Amsterdam

The global hernia mesh devices market is expected to reach USD 199.6 million by 2025, based on a new report by Grand View Research, Inc. The market is expected to grow over the forecast period owing to increase in incidence of hernia, high adoption of meshes in surgeries due to factors such as cost-effectiveness, reduced pain, reduced operative time, and high availability of products in the market. 

The reimbursement scenario for hernia mesh is favorable, which encourages patients to opt for open or laparoscopic surgery. Patients have easy access to detailed reimbursement codes and ratios, which are made available by government and industry players. The codes are granulated to types of hernias, (primary or recurrent) and method of surgery (open or laparoscopic).

Furthermore, technological advancements and new products introduction, such as TELA Bio, are driving the overall market growth. In 2010, PROCEED Ventral Patch (PVP) device was launched by Ethicon for the treatment of umbilical hernia. In 2016, GORE SYNECOR biomaterial, a product of W. L. Gore & Associates, was approved by FDA as a repair solution for ventral hernia